Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020538 (
hypertension
)
170,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aggressive
immunosuppressive therapy should be considered for patients with proliferative lupus nephritis as the risk for progression to end stage renal disease is high. Intermittent intravenous cyclophosphamide therapy improves renal survival; longer duration of therapy is associated with fewer relapse of nephritis and decreased risk of diminished renal function. While azathioprine therapy does not differ statistically from steroids alone in prolonging renal survival, this therapy may be considered in patients with few risk factors for progression to renal insufficiency. Methylprednisolone as a single therapy does not prolong renal survival compared with regimens including cyclophosphamide. Plasmapheresis remains under study but has not shown additional benefit in treatment of severe lupus nephritis. The potential roles for cyclosporin A and mycophenylate mofetil in the therapy of proliferative lupus nephritis remain to be defined. Supportive care including rigorous control of
hypertension
, consideration of angiotensin receptor inhibition or blockade to reduce proteinuria and prolong renal function, control of hyperlipidemia, prevention of osteoporosis, and prevention of pregnancy remain important clinical goals. Current research efforts focus on genetic and socioeconomic factors involved in racial differences in expression of lupus nephritis, hormonal manipulation to preserve gonadal function during cyclophosphamide therapy, and the potential impact on lupus activity of estrogen-containing oral contraceptives or postmenopausal hormone replacement therapy.
...
PMID:Immunosuppressive therapy of lupus nephritis. 988 1
Nephropathy may develop in patients with type 1 diabetes because poor glycemic control produces effects that eventually lead to glomerular scarring and renal failure. The worse and more prolonged the hyperglycemia, the greater the risk of diabetic nephropathy. In patients with type 2 diabetes, hyperglycemia, as well as insulin resistance and generalized vascular disease, is involved in the pathogenesis of nephropathy. The glomerular changes of early diabetic nephropathy can be identified only by renal biopsy or by testing for microalbuminuria. Once macroalbuminuria occurs (albumin excretion rate, > 300 mg/day), usually after type 1 diabetes has been present for 10 to 15 postpubertal years, end-stage renal disease is almost inevitable. However, aggressive control of
hypertension
in diabetic patients without microalbuminuria helps avoid nephropathy, and tight glycemic control in those with microalbuminuria can avoid or delay its onset. Even when macroalbuminuria is present, treatment can prolong renal function.
Aggressive
antihypertensive therapy, especially with ACE inhibitors, can reduce renal decline by half. Avoiding circumstances that may damage the kidneys (e.g., use of radiocontrast materials or nephrotoxic drugs, dehydration, hyperlipidemia, urinary tract infection, buildup of AGEs) is critical. Some treatment methods are controversial (dietary protein restriction) or still under investigation (use of injected or oral heparin) but may help delay renal transplantation or dialysis.
...
PMID:Dealing with diabetic nephropathy. 1002 5
Essential hypertension appears to be more prevalent among blacks than among whites and has an earlier onset in blacks. Many data in this field come from studies in the African-American population.
Hypertension
-related complications, e.g. ischaemic heart disease, (end stage) renal failure and cerebrovascular disease, are encountered more often among blacks and frequently run a more severe course. Factors that might explain the racial difference in prevalence of
hypertension
and hypertensive complications include both genetic and environmental variables.
Hypertension
in blacks is characterized by salt sensitivity, a tendency towards expanded plasma volume and low plasma renin levels. Socioeconomic factors, the higher prevalence of obesity and insulin resistance may contribute to the high prevalence of
hypertension
in blacks.
Aggressive
antihypertensive therapy appears mandatory in the black hypertensive, possibly with lower goal blood pressures than the 140/90 mmHg generally recommended. Diuretic monotherapy proves to be the first-line therapy, calcium channel blockers are an attractive alternative. Black patients are frequently less responsive to monotherapy with angiotensin-converting enzyme (ACE) inhibitors and beta-blocking agents. This black/white difference in therapeutic response can, however, be eliminated by addition of a diuretic.
...
PMID:[Hypertension in the Negro patient]. 1008 50
Male mice with targeted deletion of the gene encoding the neuronal isoform of nitric oxide synthase (nNOS(-/-)) display increased
aggressive behavior
compared with wild-type (WT) mice. Specific pharmacological inhibition of nNOS with 7-nitroindazole also augments
aggressive behavior
. We report here that male mice with targeted deletion of the gene encoding endothelial NOS (eNOS(-/-)) display dramatic reductions in
aggression
. The effects are selective, because an extensive battery of behavioral tests reveals no other deficits. In the resident-intruder model of
aggression
, resident eNOS(-/-) males show virtually no
aggression
. Latency for
aggression
onset is 25-30 times longer in eNOS(-/-) males compared with WT males in the rare instances of aggressive behaviors. Similarly, a striking lack of
aggression
is noted in tests of
aggression
among groups of four mice monitored in neutral cages. Although eNOS(-/-) mice are hypertensive ( approximately 14 mmHg blood pressure elevation),
hypertension
does not appear responsible for the diminished
aggression
. Reduction of
hypertension
with hydralazine does not change the prevalence of
aggression
in eNOS(-/-) mice. Extensive examination of brains from eNOS(-/-) male mice reveals no obvious neural damage from chronic
hypertension
. In situ hybridization in WT animals reveals eNOS mRNA in the brain associated exclusively with blood vessels and no neuronal localizations. Accordingly, vascular eNOS in the brain appears capable of influencing behavior with considerable selectivity.
...
PMID:Elimination of aggressive behavior in male mice lacking endothelial nitric oxide synthase. 1049 75
Osteogenesis imperfecta (OI) is an inherited connective tissue disorder, a group that includes Ehlers-Danlos syndrome, Marfan's syndrome and pseudoxanthoma elasticum. OI is a heterogeneous disease of collagen I biosynthesis characterized by variable clinical phenotypes, including skeletal and cardiovascular manifestations. A 65-year-old man with OI who had extensive prior successful cardiac valve surgeries is described. He survived for 18 years after his initial valve surgery, but died of multiorgan failure and sepsis after repair of a spontaneous type A aortic dissection. This is the fourth reported case of aortic dissection secondary to OI and illustrates the extensive cardiovascular pathology associated with OI.
Aggressive
management of arterial dissection risk factors, such as systemic arterial
hypertension
, is advocated for patients with OI.
...
PMID:Aortic dissection: a rare complication of osteogenesis imperfecta. 1052 81
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure
defines
hypertension
as systolic blood pressure > or =140 mm Hg or diastolic blood pressure (DBP) > or =90 mm Hg. Evidence shows that even slightly elevated blood pressure significantly increases the risk of morbidity and mortality and only aggressive efforts to reduce blood pressure can significantly reduce this risk. In the recently completed
Hypertension
Optimal Treatment trial, patients were assigned to one of three target blood pressure groups, reflecting DBP goals of < or =90, < or =85, and < or =80 mm Hg.
Aggressive
antihypertensive treatment allowed more than 90% of patients to achieve goal DBP of < or =90 mm Hg. This study clearly showed that these defined goals could be safely met and even exceeded. Too few patients with
hypertension
receive the level of effective treatment achieved in clinical trials. Individuals with poorly controlled blood pressure are at significant risk for cardiovascular and cerebrovascular morbidity and mortality and represent a potentially substantial burden to the healthcare system. Setting appropriate blood pressure goals and working to meet them through aggressive antihypertensive treatment, with multiple agents if necessary, can reduce those risks.
...
PMID:Optimal blood pressure: how low should we go? 1059 62
The majority of patients with
hypertension
have one or more additional risk factors for cardiovascular disease. In planning an appropriate treatment program, it is useful to identify and stratify hypertensive patients according to their risk of developing cardiovascular, cerebrovascular, or renal disease. At particular risk are the elderly, patients with diabetes, and those with target-organ damage manifested by impaired renal function. Evidence supports increased risk in these patients, and clinical trial results demonstrate the considerable benefits realized through aggressive blood pressure (BP) control. The number of elderly individuals continues to increase in the United States and other industrialized countries. The prevalence of isolated systolic hypertension (ISH) is higher in the elderly than in younger individuals. ISH is associated with significant morbidity and mortality and should not be considered a physiologic manifestation of the normal aging process. Type 2 diabetes is also increasing in prevalence. Patients with diabetes are at increased risk for coronary heart disease, stroke, renal failure, and other cardiovascular complications.
Aggressive
treatment of elevated BP can produce dramatic decreases in the cardiovascular complications of diabetes. The incidence of end-stage renal disease has increased 2.5-fold in the past two decades, and poorly controlled BP is a major contributor to the increase. Lowering BP to levels well below the traditional goal of 140/90 mm Hg is needed to slow the progression of renal dysfunction and prevent renal failure in hypertensive patients with renal disease, whether related to diabetes or to another etiology.
Aggressive
treatment of
hypertension
in multiple-risk populations (to the goals of JNC VI and the recent WHO-ISH Guidelines for the Management of
Hypertension
) can be expected to produce significant reductions in the incidence and prevalence of stroke, heart failure, coronary heart disease, chronic renal failure, and total cardiovascular mortality.
...
PMID:Treating multiple-risk hypertensive populations. 1059 63
Hypertension
is the leading preventable cause of premature morbidity and mortality from coronary heart disease, chronic heart failure, stroke and kidney failure. Despite the remarkable advances made in the design, development, and distribution of antihypertensive drugs and the plethora of published guidelines for
hypertension
treatment over the last two decades, blood pressure control rates remain rather disappointing. In the United States, Canada, and the United Kingdom, as well as in countries with far less resources devoted to health care, fewer than one in four hypertensives are controlled. This observation remains a major source of frustration for clinicians and health policy makers alike and serves as a constant reminder for more refined strategies for
hypertension
treatment and control. The 14th International Interdisciplinary Conference on
Hypertension
in Blacks (ISHIB99), held in Toronto, Canada on July 10-14, 1999 provided a unique forum for the discussion of this issue. The recommendations discussed are summarized herein under 10 specific headings that include: (1) Renewed emphasis on health education for patients and their families; (2) Increased involvement of non-physician health care providers; (3)
Aggressive
detection, evaluation and control of attendant cardiovascular risk factors; (4) Renewed determination for clinicians to set and achieve blood pressure targets; (5) Increased patient involvement in management decisions; (6) Improved access to quality care for the "working poor" and indigent; (7) Renewed commitment to community participation; (8) Partnership with managed care and professional organizations; (9) Renewed emphasis on the importance of psychosocial factors; (10) Enhanced communication and networking among
hypertension
care providers and between providers and patients.
...
PMID:Refining strategies for the prevention and control of hypertension and related complications. 1060 54
Atherosclerosis of the carotid bifurcation is an observable sign of systemic disease driven by key risk factors and resulting in an epidemic of stroke, myocardial infarction, and vascular death worldwide.
Aggressive
integrative preventive interventions of controlling
hypertension
, hyperlipidemia, diabetes mellitus, smoking, systemic inflammation/infarction, depression, and hyperhomocyst(e)imia are needed in the medical management of these high-risk patients. Surgical indications for asymptomatic surgery may be recalled through the acronym CAROTID, which emphasizes knowledge of risk benefit to a particular patient, adequate disclosure, and physician--patient equipoise.
...
PMID:Indications for treatment of asymptomatic carotid stenosis. 1073 43
ESRD is always fatal unless recognized and treated appropriately. In the United States, the incidence of ESRD is increasing. Fortunately, both mortality among dialysis patients and the rate at which ESRD has been increasing over the past decade are declining. Obviously, the primary goal should be prevention of ESRD.
Aggressive
treatment of
hypertension
and hyperglycemia is likely to reduce the incidence of ESRD. Screening for diabetes and
hypertension
may be a fruitful approach to reduction in ESRD rates, because many patients present with renal failure after prolonged periods of undiagnosed
hypertension
or type 2 diabetes.
...
PMID:Trends in end-stage renal disease. Epidemiology, morbidity, and mortality. 1091 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>